Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review.
CBD
Alcohol
Alcohol Use Disorder
Cannabidiol
Pharmacotherapy
Journal
Alcoholism, clinical and experimental research
ISSN: 1530-0277
Titre abrégé: Alcohol Clin Exp Res
Pays: England
ID NLM: 7707242
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
22
12
2018
accepted:
20
01
2019
pubmed:
31
1
2019
medline:
7
7
2020
entrez:
31
1
2019
Statut:
ppublish
Résumé
There is substantial interest in the therapeutic potential of cannabidiol (CBD), a nonpsychoactive cannabinoid found in plants of the genus Cannabis. The goal of the current systematic review was to characterize the existing literature on this topic and to evaluate the credibility of CBD as a candidate pharmacotherapy for alcohol use disorder (AUD). Using a comprehensive search strategy, 303 unique potential articles were identified and 12 ultimately met criteria for inclusion (8 using rodent models, 3 using healthy adult volunteers, and 1 using cell culture). In both rodent and cell culture models, CBD was found to exert a neuroprotective effect against adverse alcohol consequences on the hippocampus. In rodent models, CBD was found to attenuate alcohol-induced hepatotoxicity, specifically, alcohol-induced steatosis. Finally, findings from preclinical rodent models also indicate that CBD attenuates cue-elicited and stress-elicited alcohol seeking, alcohol self-administration, withdrawal-induced convulsions, and impulsive discounting of delayed rewards. In human studies, CBD was well tolerated and did not interact with the subjective effects of alcohol. Collectively, given its favorable effects on alcohol-related harms and addiction phenotypes in preclinical models, CBD appears to have promise as a candidate AUD pharmacotherapy. This is further bolstered by the absence of abuse liability and its general tolerability. A clear limitation to the literature is the paucity of human investigations. Human preclinical and clinical studies are needed to determine whether these positive effects in model systems substantively translate into clinically relevant outcomes.
Identifiants
pubmed: 30698831
doi: 10.1111/acer.13964
pmc: PMC6910215
mid: NIHMS1008447
doi:
Substances chimiques
Cannabidiol
19GBJ60SN5
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
550-563Subventions
Organisme : NIAAA NIH HHS
ID : R01 AA025849
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA025911
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA024930
Pays : United States
Informations de copyright
© 2019 by the Research Society on Alcoholism.
Références
Neuroreport. 2002 Apr 16;13(5):567-70
pubmed: 11973447
Sci Rep. 2017 Sep 21;7(1):12064
pubmed: 28935932
Prz Gastroenterol. 2016;11(2):78-89
pubmed: 27350834
Pharmacol Biochem Behav. 2007 May;87(1):65-72
pubmed: 17482246
Pharmacology. 1980;21(3):175-85
pubmed: 7413719
Addict Biol. 2014 Sep;19(5):862-73
pubmed: 23573810
Braz J Med Biol Res. 2006 Apr;39(4):421-9
pubmed: 16612464
Lancet. 2003 May 17;361(9370):1677-85
pubmed: 12767733
Psychopharmacology (Berl). 1979;66(1):45-50
pubmed: 120541
Subst Abus. 2016 Apr-Jun;37(2):286-98
pubmed: 26928397
Subst Abuse Rehabil. 2014 Aug 08;5:87-94
pubmed: 25187751
Neuropsychopharmacology. 2018 Jan;43(1):142-154
pubmed: 28875990
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Psychol Addict Behav. 2008 Sep;22(3):372-9
pubmed: 18778130
Free Radic Biol Med. 2014 Mar;68:260-7
pubmed: 24398069
J Mol Neurosci. 2018 Sep;66(1):121-134
pubmed: 30109468
Subst Abuse. 2015 May 21;9:33-8
pubmed: 26056464
Am J Health Syst Pharm. 2007 Mar 1;64(5 Suppl 3):S12-22
pubmed: 17322178
Br J Pharmacol. 2011 Apr;162(7):1650-8
pubmed: 21182490
J Pharmacol Exp Ther. 2005 Aug;314(2):780-8
pubmed: 15878999
Pharmacol Biochem Behav. 2009 Sep;93(3):237-47
pubmed: 19410598
Psychopharmacology (Berl). 1980;71(2):181-8
pubmed: 6777818
Neuropsychopharmacology. 2018 Sep;43(10):2036-2045
pubmed: 29686308
Neurology. 2018 Apr 3;90(14):e1204-e1211
pubmed: 29540584
J Clin Psychopharmacol. 2012 Aug;32(4):558-62
pubmed: 22722516
Psychopharmacology (Berl). 1997 Jul;132(1):104-6
pubmed: 9272766
Am J Psychiatry. 2011 Feb;168(2):183-92
pubmed: 21078704
Psychopharmacology (Berl). 1979 Aug 8;64(2):243-6
pubmed: 115049
Am J Med. 2017 Feb;130(2):124-134
pubmed: 27984008
Am J Drug Alcohol Abuse. 2010 Mar;36(2):102-5
pubmed: 20337506
Alcohol Clin Exp Res. 2013 Sep;37(9):1516-26
pubmed: 23647533
Br J Pharmacol. 2018 Aug;175(16):3369-3378
pubmed: 29859012
Exp Clin Psychopharmacol. 2008 Aug;16(4):332-40
pubmed: 18729688
Clin Neuropharmacol. 2010 Sep-Oct;33(5):250-3
pubmed: 20811276
J Clin Psychopharmacol. 2010 Jun;30(3):318-22
pubmed: 20473070
Br J Clin Pharmacol. 2013 Dec;76(6):846-57
pubmed: 23601084
Chem Biodivers. 2007 Aug;4(8):1678-92
pubmed: 17712814
Neurochem Res. 2005 Aug;30(8):1037-43
pubmed: 16258853
Alcohol Clin Exp Res. 2009 Jul;33(7):1294-303
pubmed: 19389183
Br J Pharmacol. 2015 Oct;172(20):4790-805
pubmed: 26218440
Front Immunol. 2016 Dec 27;7:655
pubmed: 28082989
Br J Pharmacol. 2007 Dec;152(7):1092-101
pubmed: 17876302
Oxid Med Cell Longev. 2016;2016:1543809
pubmed: 26949445
Am J Addict. 2012 May-Jun;21(3):221-32
pubmed: 22494224
Lancet. 2018 Mar 17;391(10125):1085-1096
pubmed: 29395273
Addiction. 2018 Feb;113(2):220-237
pubmed: 28940866
Epilepsy Behav. 2007 May;10(3):486-94
pubmed: 17409025
Addict Biol. 2018 Jan;23(1):154-164
pubmed: 28194850
Drug Alcohol Depend. 2002 Aug 1;67(3):323-30
pubmed: 12127203
N Engl J Med. 2018 May 17;378(20):1888-1897
pubmed: 29768152
Alcohol Alcohol. 1998 Mar-Apr;33(2):126-30
pubmed: 9566474
Psychol Med. 2015 Jul;45(10):2083-93
pubmed: 25640022
Alcohol. 2017 Dec;65:31-35
pubmed: 29084627
J Psychopharmacol. 2016 Feb;30(2):140-51
pubmed: 26577065
Psychopharmacology (Berl). 2011 Aug;216(3):305-21
pubmed: 21373791
Ann Pharmacother. 2015 Aug;49(8):897-906
pubmed: 25969570
Alcohol Alcohol. 2009 Mar-Apr;44(2):115-27
pubmed: 18940959
Addiction. 2017 Jan;112(1):51-62
pubmed: 27450931
Psychol Med. 2017 Oct;47(13):2288-2301
pubmed: 28374654
Exp Clin Psychopharmacol. 2002 Aug;10(3):248-57
pubmed: 12233985
Mediators Inflamm. 2015;2015:523418
pubmed: 25999668
Alcohol Clin Exp Res. 2012 Aug;36(8):1421-30
pubmed: 22324516
Experientia. 1981 Oct 15;37(10):1090-2
pubmed: 6273208
N Engl J Med. 2017 May 25;376(21):2011-2020
pubmed: 28538134
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8268-73
pubmed: 9653176
Am J Drug Alcohol Abuse. 2009;35(5):316-9
pubmed: 19637104
Curr Drug Saf. 2011 Sep 1;6(4):237-49
pubmed: 22129319
Genes Brain Behav. 2009 Jun;8(4):426-34
pubmed: 19243451
Pharmacol Biochem Behav. 2013 Oct;111:120-7
pubmed: 24012796
Curr Top Behav Neurosci. 2010;3:179-95
pubmed: 21161753
Drug Alcohol Depend. 2009 Oct 1;104(3):197-203
pubmed: 19570621
J Trace Elem Med Biol. 2013 Oct;27(4):355-63
pubmed: 23993482
J Abnorm Psychol. 2010 Feb;119(1):106-14
pubmed: 20141247
Pharmacol Res. 2016 Oct;112:119-127
pubmed: 26845349
Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1393-8
pubmed: 12538878
Alcohol Clin Exp Res. 2016 Jul;40(7):1368-79
pubmed: 27184259
J Clin Psychopharmacol. 2015 Feb;35(1):34-42
pubmed: 25427171
Neuropsychopharmacology. 2008 Nov;33(12):2870-7
pubmed: 18305459
Acta Neurol Scand. 2017 Jan;135(1):4-16
pubmed: 27586815
Alcohol Clin Exp Res. 2014 Jun;38(6):1481-8
pubmed: 24796492
JAMA. 2014 May 14;311(18):1889-900
pubmed: 24825644
Psychopharmacology (Berl). 2002 Jan;159(2):181-7
pubmed: 11862347
Alcohol Clin Exp Res. 2010 Jan;34(1):131-41
pubmed: 19860799
Drug Discov Today. 2017 Jan;22(1):105-110
pubmed: 27554802
JAMA. 2018 Aug 28;320(8):815-824
pubmed: 30167705
JAMA. 2007 Oct 10;298(14):1641-51
pubmed: 17925516
Int J Mol Sci. 2015 Nov 02;16(11):26087-124
pubmed: 26540040
Naunyn Schmiedebergs Arch Pharmacol. 2006 Feb;372(5):354-61
pubmed: 16489449
Psychopharmacologia. 1975 Sep 17;43(3):245-54
pubmed: 1237914
Addict Biol. 2012 May;17(3):513-27
pubmed: 22458728
Alcohol Res. 2012;34(4):432-40
pubmed: 23584109